Exploring Family Office Investment Strategies

September 5, 2024 ~ Next Phase Admin ~ Leave a comment

By Faith Patenaude, Investor Research Analyst, LSN

The Family Office Investor Fireside Chat – Strategies for Family Office Investments offers a valuable exploration of investment strategies from a panel of prominent family office investors. Moderated by Claire Jeong of Life Science Nation, this engaging discussion features insights from Katherine Hill Ritchie of Private Capital Investments, Ron Paliwoda of the Paliwoda Group, Shubhra Jain of Tarsadia Investments, and Bryan Grulke of Volcano Capital.

The panelists delve into their approaches to early-stage investments, outline their investment strategies, and discuss the distinct advantages and considerations of working with family office investors compared to traditional venture capital. Discover these expert perspectives by viewing the recorded webinar.

The discussion on family office investments continues at the upcoming RESI Boston conference. This event will feature a dedicated Family Office investor panel, offering further insights into their perspectives on early-stage investments, investment strategies, and the implications of partnering with family office investors versus traditional VCs. Additionally, RESI will host the invite-only Global Family Office Bioforum Luncheon, providing a unique opportunity to connect with key figures in family office investment.

Elevate Your Pitch at RESI: A Unique Opportunity

September 5, 2024 ~ Next Phase Admin ~ Leave a comment

By Greg Mannix, VP, EMEA Business Development, LSN

Limited Openings for 1 Medtech and 1 Therapeutics Pitch at RESI Boston!

Apply to Pitch at RESI Boston 2024

Early-stage entrepreneurs in the life sciences have an opportunity to showcase their innovations at the upcoming RESI conferences. Although the RESI Boston Innovator’s Pitch Challenge is close to fully booked, you can still apply to pitch at RESI London on Wednesday, December 4 and RESI JPM in San Francisco on Tuesday, January 14.

RESI’s Innovator’s Pitch Challenge (IPC) offers a unique advantage compared to typical company presentations. Unlike other conferences, companies pitch to a dedicated team of coordinated investors who are actively engaged, providing interactive questions and feedback throughout the process.

 Participants in the IPC will benefit from:

RESI conference registrations with 1-to-1 partnering opportunities to arrange meetings with over a hundred attending investors and licensing partners.
Exhibit a poster in the Innovator’s Pitch Exhibition Hall.
The chance to win complimentary RESI registration for future conferences.

This is a prime opportunity to gain significant exposure, connect with key industry figures, and advance your venture. Don’t miss out on this chance to make a meaningful impact!

Submit your application soon to secure your spot!

Hot Investor Profile: VC/PE Firm Specialized in Life Sciences Invests $10-40M in Venture and Growth Stage Therapeutics and Medical Device Companies

September 5, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital and private equity firm making investments in life sciences will invest as early as Series A and through growth transactions. The firm looks to invest between $10 million and $40 million per investment. The firm has a preference for funding companies with a de-risked clinical development pathway, often via established mechanisms of action, repurposed/reformulated programs, 505(b)(2)s, and/or proof of concept clinical efficacy data.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm With Family Office Ties Seeks Early-Stage Therapeutics Companies Based in USA and Europe

September 5, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital firm with ties to a family office invests mainly in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US.

The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred.

There are no specific requirements for companies’ management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Europe-Based VC Firm Invests in Pre-Seed and Seed Stage Healthtech Companies With Strong Data or Computing Component

September 5, 2024 ~ Next Phase Admin ~ Leave a comment

A venture capital firm founded in 2019 and headquartered in Europe invests in healthtech startups in Pre-Seed to Seed stages across Europe as well as in the U.S., Canada, Israel, and Australia. Typical check size ranges from €200k-1.5M EUR, and the firm can lead rounds, co-invest, or follow.

The firm invests in healthcare companies that involves data information, technology, hardware, software, AI, and medtech that includes a strong data or computing component. The firm will not look at traditional medical devices such as surgical devices that does not have data components or traditional biotech such as therapeutics and drug development. The firm has broad indications and will look at different needs across the entire healthcare system such as need-based solutions for providers, better operations on the backend, direct solutions for patients, clinical trial needs, payer and insurance company solutions, and medical education platforms.

The firm often takes a board or observer seat though not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: VC Firm Looks for Innovative Digital Health Technologies With High Potential in US Markets, Investing Up to $15M

September 5, 2024 ~ Next Phase Admin ~ Leave a comment

A USA-based venture capital firm that focuses on partnering with digital health startups that will redefine the healthcare system. The firm partners with incubation, Seed, Series A, and Series B startups to drive innovation within the healthcare system to create fundamental change with typical check sizes of $1-15m. The firm is excited about all opportunities in digital health and invests across all business models (B2B, B2B2B, and DTC) and customer segments (payer, provider, employer, pharma, government, customer, etc.). The firm is willing to invest globally and focuses on companies who are looking to commercialize in the US.

The firm is interested in all sectors of digital health, which generally includes five distinct areas: consumer gateways, data liquidity and analytics, tech-enabled services, digital therapeutics, and vertical reimagination.

The firm prefers to lead or co-lead its investments across all stages.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

The RESI Boston Innovator’s Pitch Challenge Finalists Announced!

August 29, 2024 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Get ready for a showcase of groundbreaking ideas at the upcoming RESI Boston 2024! The Innovator’s Pitch Challenge (IPC) will feature 11 dynamic sessions where finalist companies present their cutting-edge innovations to a panel of distinguished investors and industry experts. In addition to their live pitches, each finalist will display their technology in the RESI exhibit hall, providing an excellent opportunity for attendees to delve deeper into their visionary projects.

Meet the Innovator’s Pitch Challenge Finalists

Every RESI attendee will be given five pieces of “RESI Cash” to cast their votes for the most promising companies. The three companies with the most votes will be announced at the event’s close, earning them not only a coveted prize but also a feature in the RESI newsletter. This challenge offers startups a unique platform to gain visibility, actively fundraise, and network with conference attendees—many of whom are potential investors.

If you’re planning to attend RESI Boston, don’t miss the chance to witness these innovative pitches and explore the posterboards in the exhibit hall. Want to see these presentations up close and connect with the startups one-on-one? Make sure to register for the event here.